Analyst consensus rating
PTC Therapeutics Analyst Rating: Buy
Direct answer
PTC Therapeutics's consensus rating is Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $97.94.
Forecast evidence checked October 17, 2026.
Get free PTC Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $59.24
- Average price target
- $97.94
- High price target
- $137.00
- Low price target
- $62.00
- Low target gap
- +4.7%
- Target upside
- +65.3%
- High target gap
- +131.3%
- Target range width
- 126.6%
- Consensus rating
- Buy
- Analysts
- 16
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for PTC Therapeutics?
PTC Therapeutics has a verified Buy consensus. The same dataset has an average price target of $97.94.
How far are PTC Therapeutics's low and high targets from the recorded price?
The low target implies +4.7%, while the high target implies +131.3%.
How many analysts are included in PTC Therapeutics's consensus?
The verified consensus includes 16 analysts.
How is PTC Therapeutics's target upside or downside calculated?
The average target of $97.94 is divided by the recorded price of $59.24, then one is subtracted to produce +65.3%. This does not guarantee a future return.
When was PTC Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.